At a glance
| Known as | E2086 |
|---|---|
| Sponsor | Eisai |
| Mechanism | Oral orexin receptor agonist |
| Stage | Phase 2 |
| Indications | NT1 |
| Registered trials | 5 · 2 recruiting |
| Last verified | 4 Aug 2026 |
Where it stands
E2086 is Eisai's entry in the orexin agonist class and the least-covered of the mid-stage programmes. It advanced to Phase 2 with study NCT07493265, now recruiting, which evaluates efficacy and safety in adults with narcolepsy.
It got there off a Phase 1 package that included a placebo- and active-comparator-controlled study in narcolepsy type 1. Running an active comparator that early is a stronger design than the placebo-only studies typical at Phase 1, because it puts the compound against an existing treatment rather than against nothing.
Registered trials
All 5 studies on ClinicalTrials.gov that name E2086 or its development code, pulled from the registry on 4 Aug 2026.
| Registry ID | Study | Phase | Status | Primary completion |
|---|---|---|---|---|
NCT07493265 |
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyEfficacy and safety in adults with narcolepsy. Recruiting.64 participants | Phase 2 | Recruiting | 14 Feb 2027 |
NCT07308236 |
A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants10 participants | Phase 1 | Recruiting | 23 Feb 2026 |
NCT06481488 |
A Study of E2086 in Healthy Adult Participants32 participants | Phase 1 | Completed | 13 Dec 2024 |
NCT06462404 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 122 participants | Phase 1 | Completed | 17 Mar 2025 |
NCT05745207 |
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants53 participants | Phase 1 | Completed | 18 Jan 2024 |
Trial records are maintained by the sponsor and change without notice. Follow each link for current recruitment status and eligibility.
E2086 — common questions
What phase is E2086 in?
Phase 2. Study NCT07493265 is recruiting and evaluates efficacy and safety in adults with narcolepsy. It followed completed Phase 1 studies, including a placebo- and active-comparator-controlled study in narcolepsy type 1.
Who makes E2086?
Eisai, the Japanese pharmaceutical company.
Source
This entry was last checked against its primary source on 4 Aug 2026: https://clinicaltrials.gov/study/NCT07493265
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when E2086 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.